Research information only. PrecisePep is an educational library. It is not medical advice and is not intended to assist, encourage or enable self-administration. The compounds documented here are research chemicals — most are not approved for human use. Read the full disclaimer.
PrecisePep/Peptide Library/GHK-Cu
Regenerative & Tissue Repair
Glycyl-L-histidyl-L-lysine copper(II) · copper peptide · GHK
An endogenous copper-binding tripeptide with a real human topical evidence base, a large gene-expression literature, and one property no other repair peptide has: it delivers a transition metal into the body every time it is injected.
GHK is not a designed drug — it is a human peptide. It occurs naturally in plasma at around 200 ng/mL at age 20 and falls to roughly 80 ng/mL by age 60, a decline that forms the basis of most of the anti-ageing reasoning around it. It binds copper(II) with high affinity, and the copper complex is the biologically active species.
The literature here is better than for most research peptides, and different in character. Pickart and Margolina's gene-expression analysis reported that GHK modulates a very large number of human genes, resetting expression patterns toward a healthier state in several disease contexts.[1] There is genuine human evidence for topical use — improved skin firmness, elasticity, wrinkle depth and photodamage in controlled dermatological studies — and a substantial wound-healing literature.[2][3]
What there is no evidence for is repeated subcutaneous injection in humans, which is how the research community uses it. And GHK-Cu carries a risk that no other peptide on this site does: it is a delivery vehicle for copper. Copper is an essential trace mineral with a narrow window between sufficiency and toxicity, and it antagonises zinc. That is why copper-peptide protocols talk about zinc at all.
Every milligram of GHK-Cu carries copper into the body, and injected copper bypasses the tightly regulated intestinal absorption that normally protects against overload. Chronic uncontrolled copper loading disrupts the copper:zinc ratio, and severe copper excess causes hepatic and neurological injury. Serum copper, ceruloplasmin and zinc are measurable — which is why the sensible version of any GHK-Cu protocol involves labs, not guesswork about how much zinc to take.
Copper delivery and copper-dependent enzymes. GHK's primary physiological role appears to be as a copper transport peptide, moving Cu²⁺ to and from copper-dependent enzymes. Lysyl oxidase — the enzyme that cross-links collagen and elastin, giving connective tissue its tensile strength — is copper-dependent, which links copper delivery directly to matrix quality.
Extracellular matrix remodelling. GHK-Cu stimulates collagen, elastin, proteoglycan, glycosaminoglycan and decorin synthesis by fibroblasts. Crucially it also upregulates matrix metalloproteinases and their inhibitors together — meaning it drives remodelling (removal of damaged matrix and replacement with new) rather than simple deposition, which is what distinguishes regeneration from fibrosis.[3]
Gene expression modulation. The most striking claim in the literature: broad modulation of human gene expression, with reported resetting of expression patterns in models of COPD, metastatic cancer and neurodegeneration toward healthier profiles. This is transcriptomic analysis, not clinical outcome data, and it should be read as hypothesis-generating.[1]
Antioxidant and anti-inflammatory activity. GHK-Cu reduces reactive oxygen species, blocks iron-driven lipid peroxidation, and dampens inflammatory signalling — while paradoxically the copper ion itself is redox-active, which is part of why the free ion is toxic and the complexed form is not.
Angiogenesis and nerve outgrowth. Reported stimulation of blood vessel and nerve outgrowth, contributing to wound-healing effects.
Effects that have been reported. A study-tier entry means a result was published — not that the effect is established, reproducible, or transferable from a rodent to a person.
Highest confidenceReported in peer-reviewed literature, registered clinical trials, or regulatory filings. Note the model: much peptide literature is in vitro or rodent work, not human trial data.
Controlled dermatological studies of topical GHK-Cu report increased collagen, improved elasticity and reduced fine lines and photodamage in human subjects — including comparisons favourable to vitamin C and retinoic acid in some endpoints.
GHK-Cu accelerates wound closure, increases angiogenesis and improves healing quality across animal models and human wound studies, including diabetic and ischaemic wound contexts.
Direct stimulation of fibroblast collagen and GAG production demonstrated in cell culture and tissue models — the most reproducible in vitro finding for this peptide.
The tripeptide-copper complex stimulates matrix metalloproteinase-2 expression in fibroblast cultures, supporting the remodelling rather than deposition model of its action.
Transcriptomic analysis reports GHK influencing a very large fraction of human genes, with reported reversion of pathological expression signatures in disease models.
Reported enlargement of hair follicles and stimulation of growth in animal and limited human topical work.
Suppression of inflammatory cytokines and reduction of oxidative damage reported across models.
Unproven — inference onlyExtrapolated from a known mechanism, receptor profile, or adjacent compound class. Biologically plausible but not directly demonstrated for this compound in this context.
The reason it appears in injectable repair blends. Topical human evidence establishes local dermal effect; extrapolating to systemic tendon and ligament repair via subcutaneous injection is an inference, not a finding.
The most common reason GHK-Cu is added to fat-loss stacks. The collagen and elastin mechanism makes this plausible; there is no study of subcutaneous GHK-Cu for skin laxity after weight loss.
Based on gene-expression reversion findings in COPD tissue. Hypothesis-generating transcriptomics, no clinical trial.
Extrapolated from reported nerve outgrowth and from expression analyses in neurodegeneration models.
The most over-extended claim attached to this peptide. Reported reversion of aggressive tumour expression signatures in analysis is a very long way from any therapeutic claim, and copper is itself implicated in tumour angiogenesis.
Uncontrolled reportsAggregated from research-community logs, forums, vendor literature and self-reported experience. Uncontrolled, unverified, subject to placebo, polypharmacy and product-purity confounds. Lowest evidentiary weight.
Widely reported with both topical and injected use, often within four to eight weeks. The strongest anecdotal signal for this compound and the one best supported by independent evidence.
The single most cited reason for adding GHK-Cu to a metabolic stack. Uncontrolled and impossible to separate from the natural retraction that occurs over time.
Consistently reported and consistent with the wound-healing literature.
The defining practical complaint about GHK-Cu, attributed to the copper ion. Community mitigations are greater dilution, blending with BPC-157 (claimed to have local anaesthetic-like properties) and slower injection.
Reported with topical scalp use more than injection.
Reported on prolonged continuous use, and the main practical reason the community cycles copper peptides. Consistent with copper excess; almost never confirmed with a serum copper measurement.
Adverse effects, contraindications and unknowns. The grey-market tier is where under-reporting is worst: uncontrolled use produces no systematic safety surveillance at all, so absence of a reported harm is not evidence of safety.
Highest confidenceReported in peer-reviewed literature, registered clinical trials, or regulatory filings. Note the model: much peptide literature is in vitro or rodent work, not human trial data.
Topical GHK-Cu has a long cosmetic-use history with a benign local safety profile; irritation and contact sensitivity are the main reported issues.
Independent of this peptide, copper excess causes hepatic injury, neurological dysfunction and haemolysis; Wilson disease is the inherited model of what unmanaged copper accumulation does. Injected copper bypasses intestinal regulation entirely.
Copper and zinc compete for absorption and for binding to metallothionein. Sustained copper loading depresses zinc status, with downstream effects on immune function, testosterone and wound healing — the reason zinc appears in copper-peptide protocols.
No study has characterised repeated subcutaneous GHK-Cu in humans, and no dose-response for copper load from injected peptide exists.
Unproven — inference onlyExtrapolated from a known mechanism, receptor profile, or adjacent compound class. Biologically plausible but not directly demonstrated for this compound in this context.
The central risk. A milligram-level daily copper-peptide dose over months delivers a copper load that no dietary route would produce, without the intestinal gate that normally regulates it.
The community response to copper concern is zinc supplementation — which, taken chronically at high doses, causes copper deficiency, anaemia and neurological injury. Both directions of this ratio are harmful and neither is guessable without labs.
Copper is required for angiogenesis, and copper chelation has been investigated as an anti-angiogenic anti-cancer strategy. Deliberately loading copper is the opposite intervention.
Free copper ions are redox-active and generate hydroxyl radicals. The safety of GHK-Cu depends on the copper remaining complexed.
Uncontrolled reportsAggregated from research-community logs, forums, vendor literature and self-reported experience. Uncontrolled, unverified, subject to placebo, polypharmacy and product-purity confounds. Lowest evidentiary weight.
The most consistently reported adverse effect of any peptide in common use.
Reported with higher or prolonged dosing and classically associated with copper excess.
The practical driver behind blend cycling schedules.
Occasionally reported; transient blue-green tinting reflects the copper complex itself.
Figures below are documented, not recommended. Study ranges come from published protocols in the stated model; grey-market ranges are what the research community reports using and carry no safety validation of any kind.
Highest confidenceReported in peer-reviewed literature, registered clinical trials, or regulatory filings. Note the model: much peptide literature is in vitro or rodent work, not human trial data.
Human topical work uses creams and serums in fractions of a percent by weight, applied daily over weeks to months. This is the only well-characterised human dosing context for GHK-Cu.
There is no clinical dosing precedent for injected GHK-Cu in humans. Every injectable figure in circulation originates from community practice.
Unproven — inference onlyExtrapolated from a known mechanism, receptor profile, or adjacent compound class. Biologically plausible but not directly demonstrated for this compound in this context.
The mechanistically correct framing that community dosing almost never uses. What matters for the systemic risk is total elemental copper delivered per week, not milligrams of tripeptide.
Because the risk is cumulative rather than acute, defined off-periods are the standard mitigation. This is the one compound on this site where community cycling practice has a clear mechanistic justification.
If the objective is skin quality, the route with actual human evidence is topical — and it delivers no systemic copper load at all.
Uncontrolled reportsAggregated from research-community logs, forums, vendor literature and self-reported experience. Uncontrolled, unverified, subject to placebo, polypharmacy and product-purity confounds. Lowest evidentiary weight.
The typical standalone injectable range in circulation, almost always cycled.
In KLOW and GLOW the GHK-Cu share is set by blend ratio. At 3.25 mg total KLOW daily the copper-peptide component is a fraction of that — see the blend page for the arithmetic.
Common cosmetic-strength preparation, the closest community practice comes to the evidenced route.
Widely practised to offset copper loading. The Gold Standard protocol notes zinc may be needed to balance copper but cautions that daily zinc limits make bloodwork the sensible prerequisite — which is the correct instinct.
| Context | Typical amount | Frequency | Cycling reported |
|---|---|---|---|
| Standalone injectable | 1 – 2 mg | Daily | 4–8 weeks on, 4 weeks off |
| Within KLOW blend | Per blend ratio | Daily | 4 vials, then rotate off copper |
| Topical serum | 1 – 3 mg/mL | Once or twice daily | Often continuous |
| Zinc counter-balance | Per labs | Daily | Guided by serum Cu / Zn |
Serum copper, ceruloplasmin and serum zinc are inexpensive, widely available tests. GHK-Cu is the one compound on this site where the relevant risk can actually be measured rather than guessed at — which makes guessing at it a choice rather than a necessity.
Combination effects. Almost no peptide combination has been studied as a combination in humans; stack logic is overwhelmingly mechanistic inference and community practice. Each linked compound has its own page.
Highest confidenceReported in peer-reviewed literature, registered clinical trials, or regulatory filings. Note the model: much peptide literature is in vitro or rodent work, not human trial data.
No trial evidence for GHK-Cu in combination with other peptides.
Unproven — inference onlyExtrapolated from a known mechanism, receptor profile, or adjacent compound class. Biologically plausible but not directly demonstrated for this compound in this context.
Matrix remodelling plus angiogenesis and fibroblast signalling. The secondary claim — that BPC-157 blunts GHK-Cu injection pain — is a widely repeated community observation with no pharmacological characterisation.
Structural remodelling paired with systemic cell mobilisation — the two halves of "build" and "deliver".
KPV is included in KLOW partly on the argument that copper-driven local irritation and chronic inflammation both need suppressing for matrix work to proceed.
Zinc is added to counteract copper loading, which means it is being used against the compound rather than with it. Balance is the goal; the ratio is measurable.
The skin-elasticity rationale for combining copper peptides with retatrutide-class weight loss. Plausible, untested.
Uncontrolled reportsAggregated from research-community logs, forums, vendor literature and self-reported experience. Uncontrolled, unverified, subject to placebo, polypharmacy and product-purity confounds. Lowest evidentiary weight.
GHK-Cu is the "G" in GLOW and a core component of KLOW.
The stated purpose of rotating KLOW → Wolverine is to give copper exposure a break while retaining BPC-157 and TB-500. This is the most sensible cycling rationale in the community canon.
Reported for skin-focused goals. Doubles total copper exposure without doubling the awareness of it.
Whole schedules — dosing, titration, cycle length, and off-time — as documented in trials, as proposed from mechanism, and as circulated in the research community. Reproduced for study and comparison only.
Highest confidenceReported in peer-reviewed literature, registered clinical trials, or regulatory filings. Note the model: much peptide literature is in vitro or rodent work, not human trial data.
Controlled human studies applying GHK-Cu creams daily over 12 weeks or longer with instrumented skin measurements and biopsy endpoints. The only human protocol context.
Unproven — inference onlyExtrapolated from a known mechanism, receptor profile, or adjacent compound class. Biologically plausible but not directly demonstrated for this compound in this context.
Defined on-periods with off-periods long enough for copper homeostasis to normalise, ideally verified by serum copper, ceruloplasmin and zinc rather than by symptom absence.
Because the risk is cumulative, the relevant exposure metric is total copper delivered over the year — not dose per injection.
Uncontrolled reportsAggregated from research-community logs, forums, vendor literature and self-reported experience. Uncontrolled, unverified, subject to placebo, polypharmacy and product-purity confounds. Lowest evidentiary weight.
Four vials of KLOW, then two vials of Wolverine blend at 1 mg, then back to KLOW. Zinc noted as potentially needed to balance copper, with labs recommended first because of zinc upper limits.
Standard standalone injectable cycling in circulation.
GHK-Cu is the compound in this library with the best human evidence for the thing it is actually sold for — and the route that evidence used is the one the grey market ignores. Almost everything below is a topical result being used to justify an injection.
The strongest GHK-Cu evidence is topical, in skin, at cosmetic concentrations. Injectable and systemic use has essentially no controlled human evidence for any indication on this page. GHK-Cu is also a copper delivery vehicle, and copper is an element the body has no rapid excretion route for — see the copper entry below, which is the most important item here.
GHK-Cu is listed among compounds pending PCAC review — see the regulatory status section below.
Pathophysiology
Photoaged skin shows fragmented collagen, reduced dermal thickness, and a shift in the balance between matrix synthesis and matrix degradation toward degradation.
Mechanistic rationale
Copper is a required cofactor for lysyl oxidase, the enzyme that cross-links collagen and elastin — so a copper-delivering tripeptide has an unusually direct mechanistic route into dermal matrix biology. Controlled human topical studies have reported improvements in skin density, wrinkle depth, elasticity and photodamage. This is real human evidence in the right tissue for the right claim, which makes it rare in this library.
Community reports
Topical GHK-Cu serums are a mainstream cosmetic category with a large satisfied user base. Subcutaneous injection for the same purpose is a grey-market practice with no evidence that systemic delivery outperforms putting it where you want it to work.
Components carrying the argument: Copper delivery, lysyl oxidase cofactor, matrix remodelling
Pathophysiology
Chronic wounds fail at re-epithelialisation and angiogenesis, often against a background of poor perfusion, infection and — in diabetes — impaired growth factor signalling.
Mechanistic rationale
GHK-Cu was characterised as a wound-healing factor before it was a cosmetic ingredient. It is reported to increase angiogenesis, attract immune and repair cells to the wound, stimulate collagen and glycosaminoglycan synthesis, and modulate matrix metalloproteinases. Human work exists in wound and ulcer contexts, though it is older, smaller and less consistent than the cosmetic literature.
Community reports
Used topically post-procedure — after microneedling, laser and minor surgery — and reported to speed visible recovery. Note that broken skin is a different sterility proposition from intact skin.
Components carrying the argument: Angiogenesis, collagen and GAG synthesis, MMP modulation
Pathophysiology
Androgenetic alopecia involves follicular miniaturisation driven by dihydrotestosterone, alongside perifollicular microinflammation and reduced dermal papilla signalling.
Mechanistic rationale
GHK-Cu is reported to stimulate dermal papilla cell proliferation and to have some 5-alpha reductase inhibitory activity in vitro, which is the mechanistic case people make. The evidence is small studies and in vitro work, and nothing here approaches the effect size of the two approved treatments. Copper peptides are a large commercial hair-care category, which is a reason for more scepticism about the claims, not less.
Community reports
Widely used topically alongside minoxidil. Hair regrowth assessment by self-observation is notoriously unreliable, and the timescale — six to twelve months — outruns most people’s ability to remember their starting point.
Components carrying the argument: Dermal papilla signalling, possible 5-AR inhibition
Pathophysiology
Emphysema involves destruction of alveolar tissue with a gene expression signature of upregulated inflammation and downregulated tissue repair — the TGF-beta pathway in particular.
Mechanistic rationale
A 2012 study identified 127 genes associated with emphysema severity, then used a connectivity-map approach to search for compounds predicted to reverse that signature. GHK came out of that search. The prediction was then tested: lung fibroblasts from COPD patients, which had lost the ability to contract and remodel collagen, regained it when treated with GHK at 10 nM. That is a computational hypothesis confirmed in the relevant human cells — which is a real result, and is several long steps from a treatment for a person with COPD.
Community reports
Rarely used for this in community settings, and this entry exists mainly because the study is frequently cited as though it demonstrated a clinical effect. It did not.
Components carrying the argument: TGF-beta pathway, fibroblast contractile function
Pathophysiology
Copper is an essential trace element with a narrow acceptable range. The body has no rapid excretion route — elimination is biliary and slow. Chronic excess causes hepatic injury and neurological effects, which is the mechanism of Wilson disease.
Mechanistic rationale
GHK-Cu is a copper delivery vehicle by design. Topical application at cosmetic concentrations delivers a trivial amount. Injecting 50 mg vials — the standard grey-market presentation, and the GHK-Cu content of a KLOW or GLOW vial — is a different quantity by orders of magnitude, delivered systemically, repeatedly, with no monitoring. Copper and zinc also compete for absorption and transport, so sustained copper loading can produce functional zinc deficiency.
Community reports
Community discussion of copper status is close to absent, and serum copper and ceruloplasmin are cheap, ordinary blood tests. Reports of metallic taste, nausea and abdominal discomfort at higher doses are consistent with copper excess and are usually attributed to the injection itself.
Components carrying the argument: The copper, not the peptide
Pathophysiology
Tissue remodelling, angiogenesis and gene expression normalisation are the same processes tumours exploit and the same processes repair depends on.
Mechanistic rationale
The published literature on GHK and cancer points both ways: some in vitro work reports pro-apoptotic and gene-normalising effects in cancer cell lines, and the general concern about promoting angiogenesis in the presence of a tumour applies here as it does across this library. Neither position is settled, and no human data exists in either direction.
Community reports
Not a community topic, which is itself part of the problem — the question is rarely raised before use.
Components carrying the argument: Angiogenesis and matrix remodelling; direction unresolved
| Application | Route with the evidence | Tier | The thing to know |
|---|---|---|---|
| Skin ageing / photodamage | Topical | Human RCT | Best evidence in this library for its actual use |
| Wound healing / ulcers | Topical | Human, older | Broken skin is a sterility problem |
| Hair growth | Topical | Small / in vitro | Minoxidil and finasteride have the effect size |
| COPD / lung remodelling | In vitro | Human cells | Cited as clinical; it is not |
| Copper load | Injectable | — | 50 mg vials systemically, no monitoring |
| Cancer | — | Unsettled | Literature points both ways; no human data |
For skin: sun protection is the single highest-yield intervention and nothing on this page competes with it. Topical retinoids have the strongest evidence of any topical for photoageing, and topical GHK-Cu has its own reasonable evidence — applied to skin, which is where the trials applied it.
For chronic wounds: debridement, offloading, moisture balance, infection control and glycaemic control. Specialist wound services exist because these wounds respond to systematic management rather than to a single agent.
For androgenetic alopecia: topical minoxidil and oral finasteride have the randomised evidence and the effect sizes. Low-level laser therapy and microneedling have supporting data. Copper peptides sit well below all of them.
For COPD: smoking cessation is the only intervention shown to alter the decline in lung function. Bronchodilators, inhaled corticosteroids where indicated, pulmonary rehabilitation — which improves symptoms and exercise capacity substantially — and vaccination.
Physical-chemistry reference for laboratory handling of the lyophilised material. Reproduced so that stability and concentration mathematics can be studied — see the calculator for the arithmetic and the reconstitution guide for sterile technique.
Supplied lyophilised, commonly 50 or 100 mg per vial for GHK-Cu specifically (larger than most peptides because doses are in whole milligrams). The reconstituted solution is a distinctive deep blue — that colour is the copper complex and its absence is a red flag.
Lyophilised: refrigerated or frozen, protected from light. Reconstituted: 2–8 °C. Copper complexes are light-sensitive.
Commonly 50 mg and 100 mg lyophilised vials; blend vials vary.
The blue colour indicates an intact copper complex. A colourless or discoloured solution suggests either dissociation or that the product was never GHK-Cu. Reconstitute gently — this peptide is frequently reported to sting more when handled roughly.
Regulatory status changes and differs by country. This is a summary for orientation, not legal advice — check your own jurisdiction.
Cosmetic ingredient status; no therapeutic approval. GHK-Cu is widely used and legally sold in topical cosmetic products. Injectable GHK-Cu has no approval for human use in any jurisdiction and is supplied as a research chemical.
The distinction matters: a topical copper-peptide serum is a regulated cosmetic; a vial of injectable copper peptide is an unregulated research chemical delivering a trace metal past every physiological checkpoint that normally controls it.
GHK-Cu is scheduled for review by the FDA's Pharmacy Compounding Advisory Committee before the end of February 2027, alongside Melanotan II, LL-37 (cathelicidin), Dihexa acetate and PEG-MGF — whichever of those is not this compound.
This follows the FDA's April 2026 restructuring of the Section 503A categories and the July 2026 meeting at which six peptides (BPC-157, KPV, TB-500, MOTS-c, Semax and Epitalon) were recommended for the Bulks List and one (emideltide/DSIP) was not. Nothing has been decided for GHK-Cu.
A PCAC recommendation is not an approval, and the 503A Bulks List is not a drug approval either. It is also worth knowing that July 2026 was the second round: across two sittings in October and December 2024 the same committee reviewed seven substances — among them ipamorelin, kisspeptin-10, AOD-9604, CJC-1295 and thymosin alpha-1 — and rejected all seven. Two separate things are being conflated in almost every write-up of the 2026 decision:
Regulatory and trial claims re-checked against primary sources on 16 August 2026. Checked: the 2012 COPD connectivity-map finding. Approvals, trial readouts and compounding decisions move faster than anything else on this page — a date here means someone looked, not that nothing has changed since.
Athletes subject to WADA, USADA, UKAD, NCAA or military testing should assume any peptide is prohibited unless they have verified otherwise against the current WADA Prohibited List. Several classes here (growth-hormone secretagogues, TB-4 analogues, metabolic modulators) are explicitly named. Check the current list — it is republished annually.
Links resolve to PubMed records, trial registries, publisher pages or primary documents. Where a body of work rather than a single paper is cited, the link opens a PubMed query so the full result set — including newer papers than this page — can be reviewed. Verify every claim against the primary source before relying on it.
For educational and research reference only. Nothing on this site is medical advice, a recommendation, or an instruction to administer any substance to a human being. Every figure on this page is a record of what has been reported, not a recommendation. Full disclaimer.
